Safety and Efficacy of SCT-I10A in Head and Neck Squamous Cell Carcinoma
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- Drug: PD-1
- First Posted Date
- 2019-10-31
- Last Posted Date
- 2019-12-12
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 103
- Registration Number
- NCT04146181
- Locations
- 🇨🇳
Guangxi Medical University Affiliated Tumour Hospital, Nanning, Guangxi, China
SCT-I10A Plus Standard Chemotherapy in First-line Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- Drug: Placebos+chemoDrug: SCT-I10A+chemo
- First Posted Date
- 2019-10-31
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 330
- Registration Number
- NCT04146402
- Locations
- 🇨🇳
The Third Affiliated Hospital Of Qiqihar Medical University, Qiqihar, China
Safety and Efficacy of Long-term Treatment With SCT800 in Previously Treated Hemophilia A Patients.
- Conditions
- Hemophilia A
- Interventions
- Drug: Recombinant Human Coagulation FVIII
- First Posted Date
- 2019-05-13
- Last Posted Date
- 2020-04-28
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 240
- Registration Number
- NCT03947567
- Locations
- 🇨🇳
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
Safety,Efficacy and Pharmacokinetics Evaluation of SCT800 in Previously Treated Paediatric Patients With Severe Haemophilia A.
- Conditions
- Hemophilia A
- Interventions
- Drug: Recombinant Human Coagulation FVIII
- First Posted Date
- 2019-05-13
- Last Posted Date
- 2019-05-13
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 70
- Registration Number
- NCT03947320
The Purpose of This Research Study is to Compare the Efficacy and Safety of SCT630 and Adalimumab (HUMIRA®) in Adults With Plaque Psoriasis
- Conditions
- Psoriasis
- Interventions
- Biological: AdalimumabBiological: SCT630
- First Posted Date
- 2019-04-25
- Last Posted Date
- 2021-01-29
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 330
- Registration Number
- NCT03927352
- Locations
- 🇨🇳
First Affiliated Hospital of Fourth Military Medical University, Xi'an, Shaanxi, China
Pharmacokinetics and Safety in Healthy Volunteers
- Conditions
- Healthy
- Interventions
- Drug: adalimumab-EU sourceDrug: SCT630
- First Posted Date
- 2019-04-17
- Last Posted Date
- 2021-01-29
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 146
- Registration Number
- NCT03917628
- Locations
- 🇨🇳
Beijing SHIJITAN Hospital, Beijing, Beijing, China
SCT200 Plus Platinum-based Chemotherapy in Head and Neck Squamous Cell Carcinoma
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- Drug: SCT200
- First Posted Date
- 2019-03-14
- Last Posted Date
- 2020-05-27
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 25
- Registration Number
- NCT03874741
- Locations
- 🇨🇳
Cancer hospital Chinese academy of medical sciences, Beijing, Beijing, China
Safety, Tolerability, Pharmacokinetics and Efficacy of SCT-I10A in Patients With Advanced Solid Tumors or Lymphoma
- Conditions
- Advanced Solid Tumors or Lymphoma
- Interventions
- Biological: SCT-I10A
- First Posted Date
- 2019-01-29
- Last Posted Date
- 2019-01-29
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 206
- Registration Number
- NCT03821363
- Locations
- 🇨🇳
The Fifth Medical Center of PLA General Hospital, Beijing, Beijing, China
Safety and Efficacy of SCT200 in Patients With Advanced Esophageal Squamous Cell Carcinoma
- Conditions
- Esophageal Squamous Cell Carcinoma
- Interventions
- Drug: recombinant anti-EGFR monoclonal antibody
- First Posted Date
- 2019-01-25
- Last Posted Date
- 2019-01-25
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT03817567
- Locations
- 🇨🇳
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
🇨🇳Henan Cancer Hospital., Zhengzhou, Henan, China
🇨🇳The First Hospital of Jilin University, Changchun, Jilin, China
Evaluation of SCT800 in Prophylaxis Therapy on Previous Treated Patients With Severe Hemophilia A
- Conditions
- Hemophilia A
- Interventions
- Drug: Recombinant Human Coagulation FVIII
- First Posted Date
- 2019-01-24
- Last Posted Date
- 2020-02-06
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 73
- Registration Number
- NCT03815318
- Locations
- 🇨🇳
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China